Sun Pharmaceutical Industries is exploring multiple financing routes for its proposed $12 billion acquisition of Organon & Co. Reports say lenders are considering swapping Organon bondholders into Sun Pharma debt, including a possible euro-denominated bond, while Sun Pharma also plans to raise $3 billion to $4 billion in offshore loans. Deal approvals are expected by December.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
